Researchers map immune response to HIV, say findings could inform vaccine science

In research that could help in the search for an HIV vaccine, "American researchers have minutely tracked one person's powerful immune response to the virus to see how a series of mutations led to an antibody that can defeat many HIV strains," the New York Times reports (McNeil, 4/3). "In a study published in the journal Nature, researchers showed how a virus that had recently infected an African patient battled powerful proteins called 'broadly neutralizing antibodies,' which few HIV patients have but which can target thousands of strains of HIV," the Wall Street Journal notes, adding that following the patient for two years "allowed them to pinpoint how the powerful antibodies develop and evolve -- a question that scientists have been seeking to answer for years" (McKay, 4/3). Barton Haynes of Duke University, one of the study's authors, "said the challenge now was to see if re-creating those steps could lead to a viable vaccine," BBC News writes (Gallagher, 4/3). "A Nature statement said it remained to be seen whether or not the finding could be used to develop an effective vaccine," Agence France-Presse notes (4/3).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Argonne receives $21.7 million to advance cancer and vaccine discoveries